| Original language | English |
|---|---|
| Pages (from-to) | 347-361 |
| Number of pages | 15 |
| Journal | Psychosomatics |
| Volume | 49 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2008 |
Bibliographical note
Funding Information:In the past year, Dr. de Leon has been on the advisory board of Roche Molecular Systems, Inc. He has received investigator-initiated grants from Roche Molecular Systems, Inc. , and Eli Lilly Research Foundation ; he has lectured supported by Eli Lilly, Janssen, and Roche Molecular Systems, Inc. Roche Molecular Systems, Inc. , markets the AmpliChip CYP450 microarray that detects CYP2D6 and CYP2C19 gene variations.
Funding
In the past year, Dr. de Leon has been on the advisory board of Roche Molecular Systems, Inc. He has received investigator-initiated grants from Roche Molecular Systems, Inc. , and Eli Lilly Research Foundation ; he has lectured supported by Eli Lilly, Janssen, and Roche Molecular Systems, Inc. Roche Molecular Systems, Inc. , markets the AmpliChip CYP450 microarray that detects CYP2D6 and CYP2C19 gene variations.
| Funders |
|---|
| Eli Lilly Research Foundation |
| Roche Molecular Systems, Inc. |
| Eli Lilly and Company |
| Janssen Biotech |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Arts and Humanities (miscellaneous)
- Applied Psychology
- Psychiatry and Mental health
Fingerprint
Dive into the research topics of 'A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: Part II'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver